FORM PIO-1		DATE HALL & STEWART 6		INO. 558	lic. 11 No.:
(DEST 0.04)	Com		2002941-0053	09/289,32	<u> </u>
(REV. 8-83)	Paten	t and Trademark Office	Applicant: Bachovo	hin	
	ON DISCLOSURE veral sheets if necess		Filing Date: April 9, 1999	Group: 1653	
U.S. PATENT	DOCUMENTS				
Examiner's Initials	U.S. Patent No.	Applicant	Issue Date	Class	Subclass
				<del></del>	
U.S. PATENT	APPLICATIONS				
Examiner's Initials:	Serial Number:	Applicant:	Publication Date:	Group:	Art Unit:
FOREIGN PA	TENT DOCUMEN	rs			
Examiner's	Document No.	Country	Date	Translation	
Initials				Yes	No
OTHER DOC	IMENTS				
Examiner's Initials		g Author, Title, Date, Per	rtinent Pages, Etc.)		
A	Ansorge et al. "Clin Experimental M	D26/Dipeptidyl Peptidase Medicine and Biology 421	IV in Lymphocyte Gr : 127-140, 1997.	owth Regulation	on" Advances
<u> </u>	Cordes et al. "Tra Olycosylamines"	nsition States for Hydrol Chapt. 11, pp. 429-465.	ysis of Acetals, Ketals,	Glycosides, an	nd
DP.	Wijdenes, J., "Monoclonal Antibodies (mAb) Against gp130 Imitating Cytokines Which use the gp130 for Signal Transduction", 9 <sup>th</sup> International Congress of Immunology, San Francisco, California, USA, pp. 303, 1995, The 9 <sup>th</sup> International Congress of Immunology, Publisher: 9 <sup>th</sup> International Congress of Immunology, San Francisco, CA, USA.				
EXAMINER			DATE CONS	DERED	
through citation applicant.	nitial if citation consi	dered, whether or not cite e and not considered. In	ation is in conformance	with MPEP 6 with next com	09; Draw line munication to
10914	Levid Ly	Han	8/2/04	7	

FORM PTO-14	004= 4:08PM CH 449 U.S. 1 Comm	OATE HALL & STEWART 6	172484000 ocket:		lici <sup>P</sup> . 2 No.:
(REV. 8-83)		t and Trademark Office	2002941-0053	09/289,32	<u> </u>
INFORMATIC	INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Bachove Filing Date; April 9, 1999	Group:	
U.S. PATENT	DOCUMENTS				···
Examiner's Initials	U.S. Patent No.	Applicant	Issue Date	Class	Subclass
U.S. PATENT	APPLICATIONS				
Examiner's Initials:	Serial Number:	Applicant:	Publication Date:	Group:	Art Unit:
FOREIGN PAT	TENT DOCUMENT	rs			
Examiner's Initials	Document No.	Country	Date	Translation	
TITITISTIR				Yes	No
OTHER DOCU	MENTS				
Examiner's Initials		g Author, Title, Date, Per	rtinent Pages, Etc.)		····
	Ansorge, et al., "C in Experimental M	D26/Dipeptidyl Peptidas Sedicine and Biology, 42	te IV in Lymphocyte G 1: 127-140, 1997.	rowth Regulati	on", Advances
	Cordes, et al., "Tra Glycosylamines,"	ansition States for Hydro Gandour, Richard D. and esses, Plenum Press, New	lysis of Acetals, Ketals, Schowen, Richard L.	(Rde) Transit	nd ion States of
DX.	Wijdenes, J., "Mon	nocional Antibodies (mA al Transduction", 9 <sup>th</sup> Inte	b) Against and 30 Imite	ting Catalaina	Which use an Francisco,
EXAMINER		·	DATE CONSI	DERED	
EXAMINER: In through citation i applicant.	itial if citation consideration in conformance	dered, whether or not cite and not considered. Inc	ation is in conformance	with MPEP 60 with next com	9; Draw line munication to
	savid,	Letter	8/2	104	

Form PTO-1449 (REV. 8-83)

U.S. Department of Commerce Patent and Trademark Office

Atty. Docket: 2002941-0053

In re Application No. 09/289,321

INFORMATION
DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant: Bachovchin

Filing Date: April 9, 1999

Group: 1653

## U. S. PATENT DOCUMENTS

Examiner's Initials	U.S. Patent No.	Applicant	Issue Date	Class	Subclas
	* 4,318,904	Shaw et al.	March 9, 1982	514	18
	* 4,443,609	Oude Alink et al.	April 17, 1984	548	
	* 4,499,082	Shenvi et al.	February 12, 1985	514	2
	* 4,582,821	Kettner et al.	April 15, 1986	514	18
\	* 4,636,492	Kettner et al.	January 13, 1987	514	18
$\mathcal{O}_{\mathcal{O}}$	* 4,644,055	Kettner et al.	February 17, 1987	530	330
	* 4,652,552	Kettner et al.	March 24, 1987	514	18
	* 4,935,493	Bachovchin et al.	June 19, 1990	530	331
	* 4,963,655	Kinder et al.	October 16, 1990	530	331
	* 5,093,477	Mölling et al.	March 3, 1992	530	328
	* 5,187,157	Kettner et al.	February 16, 1993	514	18
	* 5,215,926	Etchells, III et al.	June 1, 1993	436	501
	* 5,242,904	Kettner et al.	September 7, 1993	514	18
XX	* 5,250,720	Kettner et al.	October 5, 1993	558	288
	* 5,288,707	Metternich	Реблиату 22, 1994	514	19
	* 5,296,604	Hanko et al.	March 22, 1994	546	169
	* 5,329,028	Ashkenazi et al.	July 12, 1994	548	548
	<b>*</b> 5,378,624	Berenson et al.	January 3, 1995	435	239
	* 5,384,410	Kettner et al.	January 24, 1995	548	405
, ,	* 5,444,049	de Nanteuil et al.	August 22, 1995	514	18
WR.	* 5,462,928	Bachovchin et al.	October 31, 1995	514	19

		Department of Commerce t and Trademark Office	Atty. Docket: 2002941-0053	In re A 09/289	pplication No ,321
INFORMATION DISCLOSURE STATEMENT			Applicant: Bachovchin		
(Use s	everal sheets if necesso	ary)	Filing Date: April 9, 1999	Group: 1653	
A 10	* 5,506,130	Peterson et al.	April 9, 1996	435	240.1
<u> </u>	* 5,527,923	Klinger et al.	June 18, 1996	548	570
	* 5,543,396	Powers et al.	August 6, 1996	514	19
	* 5,554,728	Basava et al.	September 10, 1996	530	327
	* 5,635,386	Palsson et al.	June 3, 1997	435	372
	* 5,635,387	Fei et al.	June 3, 1997	435	378
X	* 5,646,043	Emerson et al.	July 8, 1997	435	373

## FOREIGN PATENT DOCUMENTS

Examiner's Initials	Document No.	Country	Date	Translation	
				Yes	No
	DD158109	Germany	29 December 1982		X
	DD270382A1	Germany	26 July 1989		X
	DD296075A5	Germany	21 November 1991		X
	EP 0356223A2	Europe	28 February 1990	х	
$\bigcap_{i} \int_{-\infty}^{\infty} \int_{$	EP 0371467A2	Europe	6 June 1990		X
XX	* EP 0420913B1	Europe	15 November 1995		
	* EP 0471651A2	Ешторе	19 February 1992		
	EP 0481311A2	Europe	22 April 1992		X
	EP 0615978A1	Europe	21 September 1994		X
	EP 0688788A1	Europe	27 December 1995		X
	* WO 89/03223	PCT	20 April 1989		
	* WO 91/16339	PCT	31 October 1991		
XX	* WO 91/17767	PCT	28 November 1991		

Form PTO- (REV. 8-83)	EV. 8-83)  U.S. Department of Commerce Patent and Trademark Office		Atty. Docket: 2002941-0053	In re Application No 09/289,321
	NFORMATION LOSURE STATEMEN	T	Applicant: Bachovchin	
(Use	several sheets if necessa	(עד	Filing Date: April 9, 1999	Group: 1653
TH	* WO 92/12140	PCT	23 July 1992	
)	* WO 92/17490	PCT	15 October 1992	
	* WO 93/02057	PCT	4 February 1993	
	* WO 93/05011	PCT	18 March 1993	
	* WO 93/08259	PCT	29 April 1993	
	* WO 93/10127	PCT	27 May 1993	
	* WO 93/16102	PCT	19 August 1993	
	* WO 94/03055	PCT	17 February 1994	
	* WO 94/09132	PCT	28 April 1994	
~ <del>\                                   </del>	* WO 94/20526	PCT	15 September 1994	
	* WO 94/25873	PCT	10 November 1994	
	* WO 94/28915	PCT	22 December 1994	
	* WO 94/29335	PCT	22 December 1994	
	* WO95/11689	PCT	4 May 1995	
	WO95/15309	PCT	6 June 1995	x
	* WO 95/15309	PCT	8 June 1995	
	* WO 95/12618	PCT	11 May 1995	
	* WO 95/29190	PCT	2 November 1995	
	* WO 95/29691	PCT	9 November 1995	
	* WO 95/34538	PCT	21 December 1995	
	* WO 96/40858	PCT	19 December 1996	
	* WO 96/40263	PCT	19 December 1996	
	WO 98/00439	PCT	8 January 1998	x
W	WO 98/50046	PCT	12 November 1998	X
V.F	WO 98/50066	PCT	12 November 1998	X

Form PTO-1449 U.S. Department of Commerce (REV. 8-83) Patent and Trademark Office		Atty. Docket: 2002941-0053	In re Application No. 09/289,321		
	FORMATION SURE STATEMENT		Applicant: Bachovchin		
(Use ser	(Use several sheets if necessary)		Filing Date:	Group:	
		April 9, 1999	1653		
	WO 99/16864	PCT	8 April 1999	X	
Examiner's Initials	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
X	Immun. Rev., 157:13-4	10 <u>, (</u> 1997)	phocytes: Biology and I	i	
	Ansorge, et al., "CD26	Dipeptidyl Peptidase P	in Lymphocyte Grewth	Regulation", 127-140.	
NK .	Dimerization in Biolog	roxumity Versus Allost zv". <i>Chemistry &amp; Riolo</i> e	ery; The Role of Regulat	ed Protein	
D.L	Dimerization in Biology", Chemistry & Biology, 1:131-136, (1994)  * Bachovchin, W.W., et al., "Inhibition Of IGA 1 Proteinases From Neisseria Gonorrhoeae And Hemophilus Influenzae By Peptide Prolyl Boronic Acids", J. Biol. Chem., 265:3738- 3743 (1990).				
	* Bailey, P.D., "An Introduction To Peptide Chemistry", Wiley Publishers, 1-81, (1990)				
	* Barton, R.W.J., et al., "Binding Of The T Cell Activation Monocional Antibody Tal To Dipeptidyl Peptidase IV", J. Leukocyte Biology, 48:291-296 (1990).				
	Baugh, R., et al., "Role Destruction", Proteinas	and Potential Therapeur	tic Value of Proteinase Ir	thibitors in Tissue	
	* Blumenstein, et al., "S Biophysical Research C	Synthetic Non-Peptide Learning 163(2):	abibitors of HIV Protease 980-87, 1989.	e" Biochemical and	
	* Bodanszky, M., "Prine	ciples Of Peptide Synth	esis", Springer-Verlag, 1	6: (1984)	
	* Bodanszky, M., "The	Practice Of Peptide Sym	thesis", Springer-Verlag	, 21: (1984)	
	* Bodanzky, M., "Peptio	de Chemistry, A Practic	al Textbook", Springer-V	Verlag, (1988) 1-9.	
	* Boros, L.G., et al., "FI Conformations", Tetrah		teres-Tools For Controlli -6036 (1994)	ng Peptide	
	* Brady, L., and Dodsor	ı, G., "Reflections On A	Peptide", Nature, 368:6	92-693, (1994)	
	* Brander, et al., "Heter	ogeneous T Cell Respor	ises to β-Lactam-Modifie	ed Self-Structures Are	
			mmunol. 155 (5):2670-2 s in Human Membranous		
_	Nephrology, Dialysis, Ti	ransplantation 7 Supp.	i in flumati Memoranous I: 21-24. (1992).	inebutobatua.	
		aracterization Of A Nov	el Rat Thymocyte Costin	nulating Antigen By	
V	* Bristol, L.A., et al., "T	hymocyte Costimulatin ilocyte, Macrophage, T	g Antigen is CD26 (Dipe Lineage Cell Proliferation	ptidyl-Peptidase IV), on Via CD26," <i>J.</i>	
	Bristol, et al., "Inhibition Granulocyte/Macrophag Blood, 85(12): 3602-360	n of CD26 Enzyme Acti e Colony Formation and	vity with Pro-boropro Sti I Thymocyte Proliferation	imulates Rat n In Vitro",	

Form PTO-1449 U.S. Department of Commerce Atty. Docket: In re Application No. (REV, 8-83) Patent and Trademark Office 2002941-0053 09/289.321 INFORMATION DISCLOSURE STATEMENT Applicant: Bachovchin Filing Date: Group: (Use several sheets if necessary) April 9, 1999 1653 \* Bungy, et al., "Mapping of T Cell Epitopes of the Major Fraction of Rye Grass Using Peripheral Blood Mononuclear Cells From Atopics and Non-Atopics. II. Isoallergen Clone 5A of Lolium Perenne Group I (Lol p I). Eur. J. Immunol. 24 (9):2098-2103 (1994). \* Chan, et al., "Archives of Ophthalmology 113 (5):597-600 (1995). \* Chazenblak, et al., "Human Organ-Specific Autoimmune Disease", Molecular Cloning and Expression of an Autoantibody Gene Repertoire For a Major Autoantigen Reveals an Antigenic Immunodominant Region and Restricted Immunoglobulin Gene Usage in the Target Organ, J. Clinical Investigation 92 (1):62-74 (1993). \* Colowick, S., et al., "Methods In Enzymology", Pp. 220-225, Vel \* Cordes, B., et al., "Transition States For Hydrolysis Of Acetals, Ketals Glycosides, And Glycosylamines", Chapter 11, Pp. 429-465 \* Coutts, et al., "Structure-Activity Relationships of Boronic Acid Inhibitors of Dipeptidyl Peptidase IV. 1. Variation of the P<sub>2</sub> Position of X<sub>aa</sub> -boroPro Dipeptides", J. Med. Chem., 39: 2087-94, 1996. \* Dang, N.H., et al., "Cell Surface Modulation of CD26 By Anti-1F7 Monocional Antibody: Analysis Of Surface Expression And Human T Cell Activation", J. Immunol., 145:3963-3971 (1990).\* Darcy, et al., "Protection of Mice and Nude Rats Against Toxolasmosis by A Multiple Antigenic Peptide Construction Derived From Toxoplasma Gondii P30 Antigen", J. Immunol. 149 (11):3636-3641 (1992). \* Darmoul, D., et al. "Dipeptidyl Peptidase IV (CD26) Gene Expression in Enterocyte-like Colon Cancer Cell Lines HT-29 And Caco-2; Cloning Of The Complete Human Coding Sequence And Changes of Dipeptidyl Peptidase IV mRNA Levels During Cell Differentiation," J. Biological Chemistry, 267:220-2208 (1992). \* Daw, et al., "Glutamic Acid Decarboxylase Autoantibodies in Stiff-Man Syndrome and Insulin-Dependent Diabetes Mellitus Exhibit Similarities and Differences in Epitope Recognition", J. Immunol. 156 (2): 818-825 (1996). \* De Caestecker, M.P., et al., "The Detection Of Intercytoplasmic Interleukin 1 (Alpha) Expression In Human Monocytes Using Two Colour Immunofluorescence Flow Cytometry", J. Immunol. Methods 154:11-20 (1992). \* Demuth, H.U., et al. "Design Of (Omega-N-(O-Acyl)Hydroxy Amid) Aminodicarboxylic Acid Pyrrolidides As Potent Inhibitors Of Proline-Specific Peptidases", FEBS Lett., 320:23-27, (1993) \* Dudler, et al., "Carbohydrate-Dependent, HLA Class II-Restricted, Human T Cell Response to the Bee Venom Allergen Phospholipase A2 in Allergic Patients", Eur. J. Immunol. 25 (2):538-542 (1995). \* Duke-Cohan, J.S., et al., "Targeting Of An Activated T-Cell Subset Using A Bispecific Antibody-Toxin Conjugated Directed Against CD4 AND CD26", Blood, 82:2224-2234.,

Form PTO-1449 U.S. Department of Commerce Atty. Docket: In re Application No. (REV, 8-83) Patent and Trademark Office 2002941-0053 09/289.321 INFORMATION DISCLOSURE STATEMENT Applicant: Bachovchin (Use several sheets if necessary) Filing Date: Group: April 9, 1999 1653 Dupont, B., "Immunology Of Hematopoietic Stem Cell Transplantation: A Brief Review Of Its History", Immun. Rev., 157:5-12. (1997) \* Ebenbichler, C., et al., "Structure-function Relationships Of The HIV-1 Envelope V3 Loop Tropism Determinant: Evidence For Two Distinct Conformations", Aids 7:639-46 (1993). \* El Far, et al., "Antigens Associated with N- and L-Type Calcium Channels in Lambert -Eaton Myasthenic Syndrome", J. Neurochemistry, 64 (4): 1696-1702 (1995).

\* Fauci, A.S., "The Human Immunodeficiency Virus: Infectivity And Mechanisms Of Pathogenesis", Science, 239:617:722 (1988). \* Fleisher, B., et al., "Triggering of Cytotoxic T Lymphocytes and NK Cells Via The Tp 103 Pathway is Dependent On the Expression Of The T Cell Receptor/CD3 Complex", J. Immuno,,. 141:1103-1107. \* Flentke, G.R., et al., "Inhibition Of Dipeptidyl Aminopeptidase IV (DP-IV) By XAA-Boropro Dipetides And Use Of These Inhibitors To Examine The Role Of DP-IV IN T-Cell Function", Proc. Natl. Acad. Sci. USA, 88:1556-1559, (1991) \* Freeman, et al., "T and B Cell Reactivity to Adrenal Antigens in Autoimmune Addison's Disease" Clinical & Experimental Immunology 88 (2): 275-279 (1992) Goodman, et al., "Cellular Immunity to Cartilage Aggrecan Core Protein in Patients with Rheumatoid Arthritis and Non-Arthritic Controls", Annals of the Rheumatic Diseases, 55: 40-46, 1996. \* Goodman, M., and Chorev, M., "On The Concept Of Linear Modified Retro-Peptide Structures", Accounts of Chemical Research, 12:1-7 (1979) Goodstone, et al., "Cellular Immunity to Cartilage Aggrecan Core Protein in Patients with Rheumatoid Arthritis and Non-Arthritic Controls" Annals Of The Rheumatic Diseases **55**(1):40-46 (1996). \* Guichard, G., et al. "Partially Modified Retro-Inverso Pseudopeptides As Non-Natural Ligands For The Human Class I Histocompatibility Molecule HLA-A2, J. Med. Chem., **39**:2030-2039, (1996) \* Günther, U.L., et al., "Solution Structures Of The DP IV (CD26) Inhibitor Val-BoroPro Determined By NMR Spectroscopy", Magnetic Resonance in Chem., 33:959-970, (1995) Gutheil, W.G., et al., "Separation Of L-PRO-DL-Boropro Into Its Component Diastereomers And Kinetic Analysis Of Their Inhibition Of Dipeptidyl Peptidase IV. A New Method For The Analysis Of Slow, Tight-Binding Inhibition", Biochemistry, 32:8723-8731, (1993) \* Hall, et al., "Immunogenetics of Dermatitis Herpetiformis", Seminars in Dermatology, 10(3):240-245 (1991). \* Hart, et al., "Design of Experimental Synthetic Peptide Immunogens for Prevention of HIV-1 and HTLV-1 Retroviral Infections", Pharmaceutical Biotechnology 6:821-845 (1995). \* Hegen, M., et al. "Enzymatic Activity Of CD26 (Dipeptidylpeptidase IV) Is Not Required For Its Signalling Function In T Cells", Immunobiology, 189:483-493, (1993) \* Hegen, M., et al. "Function Of Dipeptidylpeptidase IV (CD26, TP103) In Transfected Human T Cells", Cell Immunol., 146:249-260, (1993)

			T Total		
Form PTO-144 (REV. 8-83)	9 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket: 2002941-0053	In re Application No. 09/289,321		
11	ORMATION SURE STATEMENT	Applicant: Bachovchin			
(Use several sheets if necessary)		Filing Date: April 9, 1999	Group: 1653		
	* Hegen, M., et al., "The T Cell Triggering Mo (1990).	lecule Tp 103, J. Immur	nol., 144:2980-2914		
	* Heins, J., et al., "Mechanism of Proline-Spec Dipeptidyl Peptidase Peptidase IV From Pig K From Flavobacterium Meningosepticum", Bioc * Ikagawa, et al., "Single Amino and Acid Sub Cry J-1) Derived Peptide Induced Alterations in Receptor Antagonism" J. Allergy & Clinical In	idney and Proline-Speci hemica Biophysica Acta, stitutions on a Japanese ( n Human T Cell Respons	fic Endopeptidase , <b>954</b> :161-169 (1988). Cedar Pollen Allergen ses and T Cell		
	* James, et al., "Peptide Autoantigenicty of the Small Nuclear Ribonucleoprotein C" Clinical & Experimental Rheumatology, 13 (3):299-305 (1995).  * Jameson, B.A., et al., "A Rationally Designed CD4 Analogue Inhibits Experimental Allergemental Allergement				
	Encephalomyelitis", Nature, 368:744-746, (1994).  * Janeway, C., et al., "Immunobiology - The Immune System In Health And Disease",  Current Biology LTD, Chapter 12, pp. 1-35, (1994).  * Jardetzky, T.S., et al., "Three-Dimensional Structure Of A HumanClass II				
	Histocompatibility Molecule Complexed With Superantigen, Nature, 368:711-718 (1994)  * Jiang, et al., "Inhibition of Human Immunodeficiency Virus Type I Infection in a T-Cell Line (CEM) by New Dipeptidyl-Peptidase IV (CD26) Inhibitors", Res Viral, 148: 255-266,				
	* Jorgensen, J.L., et al., "Molecular Component Immunol. 10:835-873 (1992).	s Of T-Cell Recognition	," Annu. Rev.		
	* Kalluri, et al., "Indentification of the Alpha 3 Autoantigen in Antibasement Membrane Disease American Society Of Nephrology 6 (4):1178-11	se and Goodpasture Synd			
	* Kameoka, J., et al., "Direct Association Of Ac Antigen, CD26", Science, 261:466-469, (1993)		h A T Cell Activation		
	* Kameoka, Jr., et al., "Differential CD26-Medi Pathways After CD6-Depleted Allogeneic Bone 1137, (1995)	Marrow Transplantation	a", Blood 85:1132-		
	* Karges, et al., "Self and Non-Self Antigen in l Mechanisms", Molecular Aspects Of Medicine	16(2):29-213 (1995).			
	* Kelly, T.A., et al., "Immunosuppressive Boron Conformation And Activity", J. Am. Chem. Soc. * Kelly, T.A., et al., "The Efficient Synthesis And Extension Synthesis Synthesis And Extension Synthesis Sy	, 115:12637-12638, (199 ad Simple Resolution Of	A Proline Boronate		
V	Ester Suitable For Enzyme Inhibition Studies", Tetrahedron 49:1009-1016 (1993).  * Kettner, C.A. and Shenvi, A.B., "Peptide Boronic Acid Inhibitors Of Trypsin-Like Proteases Their Preparation And Use As Anticoagulants And Inflammation Inhibitors", Chemical				
DL	Abstracts, (1990), 112:80 (91790c).  * Kettner, C.A., et al., "Kinetic Properties Of The Peptide Boronic Acids", Biochemistry, 27:7682		ic Protease To		

Form PTO-14 (REV, 8-83)	Patent and Trademark Office	Atty. Docket: 2002941-0053	In re Application No. 09/289,321	
	INFORMATION DISCLOSURE STATEMENT		1	
(Use several sheets if necessary)		Filing Date: April 9, 1999	Group: 1653	
	* Kinder, D., et al., "Analogues of Carbamyl A 33:819-823 (1990).	Aspartate as Inhibitors" J. Med. Chem.,		
	* Kokowa, et al., "Detection of Platelet Antige Thrombocytopenic Purpura by Flow Cytometry Immunoblotting: A Comparative Study", Eur. * Kubota, T., et al., "Diipepidyl peptidase IV (I Lymymphocytes Of Mrl/Mp-Ipr/lpr Mice Com	y, Antigen-Capture ELIS. J. Hematology <b>50</b> (2): 74 DP IV) Activity In Serum	A, and 4-80 (1993) and On	
	* Kubota, T., et al., "Involvement Of Dipeptidyl Peptidase IV In An In Vivo Immune Response", Clin. Exp. Immunol., 89:192-197, (1992).  * Kuchroo, V.K., et al., "A Single TCR Antagonist Peptide Inhibits Experimental Allergements and the state of the st			
	Encephalomyelitis Mediated By A Diverse T Cell Repertoire", J. Immunol. 153:3326-3336 (1994).  * Kuchroo, V.K., et al., "Cytokines And Adhesion Molecules Contribute To The Ability of Myelin Proteolipid Protein-Specific T Cell Clones To Mediate Experimental Allergic Encephalomyelitis", J. Immunol. 151:4371-4382 (1993).			
<b>V</b>	* Kuchroo, V.K., et al., "Experimental Allergic Encephalomyelitis Medicated By Cloned T Cells Specific For A Synthetic Peptide of Myelin Proteolipid Protein. Fine Specificity And T Cell Receptor V Beta Usage", J. Immunol. 148:3776-3782 (1992).			
	* Kuchroo, V.K., et al., "Induction Of Experime Proteolipid-Protein-Specific T Cell Clones and S (1991).	Synthetic Peptides", Path	nobiology <b>59</b> :305-312	
	* Kuchroo, V.K., et al., "T Cell Receptor (TCR) Experimental Autoimmune Encephalomyelitis: Mice", J. Experimental Medicine 179:1659-1664	Studies with TCR V Bet		
	* Kuchroo, V.K., et al., "T-cell Receptor Alpha Specific Suppressor Cell Function", <i>Proc. Natl.</i>	Acad. Sci. USA 88:8700-	8704 (1991).	
	* Linington, et al., "Cell Adhesion Molecules of Tissue-Specific Autoantigens: Induction of Expe Protein-Specific T Cell Lines", Eur. J. Immunol.	erimental Allergic Meuri 22 (7): 1813-1817 (199	tis (EAN) by PO 2).	
	* Linsley, P.S., et al., "Effects of Anti-gp 120 Monocional Antibodies On CD4 Receptor Binding By The Env Protein Of Human Immunodeficiency Virus Type 1", J. Virology 62:3695-3702 (1988).			
	* Liu, et al., "Molecular Mapping of a Pathogeni with Experimentally Induced Murine Bullous Pe (1995).	mphigoid" J. Immunol. 1	<b>.55</b> (11): 5449-5454	
	* Lopez, et al., "Characterization of SPf(66)n: A Vaccine" Vaccine, 12 (7):585-591 (1994).			
DK.	Luftig, et al., "Update on Viral Pathogenesis", Re Illustrates the Paths Being Taken in Viral Pathog 1990.			

Form PTO-14- (REV. 8-83)	49 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket: 2002941-0053	In re Application No. 09/289,321	
	FORMATION			
DISCLO	SURE STATEMENT	Applicant: Bachovchi	n	
(Use sen	veral sheets if necessary)	Filing Date: April 9, 1999	Group: 1653	
	* Marguett, et al., "cDNA Cloning for Mouse T Multifunctional Ecto-Dipeptidyl Peptidase IV ( Proteases", The Journal of Biological Chemistr * Matteson, D., et al., "Synthesis And Propertie	(CD26) Included in a Sul v. <b>267</b> (4): 2200-2208, 19	ogroup of Serine	
	Organometallics, 3:1284-1288, (1984).			
	* Mittrucker, H.W., et al. "The Cytoplasmic Ta Required For Signaling Via CD26", Eur. J. Imm	nunol., <b>25</b> :295-297. (19	95)	
	* Morimoto, C., et al., 1F7 "A Novel Cell Surface Molecule, Involved in Helper Fund CD4 cells". J. Immunol., 143:34030-3439 (1989) and published expatum appears in Immunology 144 (5):2027 (1990).			
	194, (1994).	The Progression To Aids", Science, 265:193-		
	<u>(1)</u> : 30-37 (1996).	tat and Larger Mammals" J. Clinical Investigation 96		
	* Nardelli, et al., "A Chemically Defined Synthetic Vaccine Model for HIV-1", J. Immu 148 (3): 914-920 (1992).			
V	Publication, Pp. 1-257, (1994).	s And Their Receptors", Sambrook and Tooze		
XX	* O'Brien, et al., "An Immunogenetic Analysis of Dust Mite Allergen Der p2: Identification of Hig Localization of T-Cell Epitopes" <i>Immunology</i> 8	gh- and Low-Responder	n of the Major House HLA-DQ Alleles and	
	* Panina-Bordignon, P., et al., "Universally Imm Binding To Human MHC MHC Class II And Pro Immunol. 19:2237-2242 (1989).	nunogenic T Cell Epitope omiscuous Recognition I	By T Cells", Eur. J.	
	* Ostresh, et al., "Generation and Use of Nonsup Combinatorial Libraries", Methods in Enzymolog	gy, <b>267</b> : 220-234, 1996		
	* Perry, et al., "Autoreactive T Cell Specificity in NZB Mouse", Eur. J. Immunol. 26(1): 136-141 (	1996).	ic Anemia of the	
	* Perstorp Biotec Company, "Molecular Biology	Catalog", (1994)		
	Summary" US Dept. of Health and Human Servi			
	* Protti, et al., "Myasthenia Gravis: Recognition MolecularLevel" <i>Immunol. Today</i> 14 (7):363-36	8 (1993).		
V	transforming growth factor- 1 (TGF- 1) in stimu Immunology Letters, 58:29-35, (1997).	eptidase IV (DP IV, CD26) induces secretion of		
X	* Reynolds, et al., "T and B Epitope Determination Peptides for the Schistosoma Mansoni Experiment Immunol. 152 (1):193-200 (1994).	on and Analysis of Multinatel Vaccine Triose-Phos	ple Antigenic phate Isomerase", J.	

Form PTO-14 (REV. 8-83)	49 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket: 2002941-0053	In re Application No. 09/289,321	
	FORMATION SURE STATEMENT	Applicant: Bachovchin		
(Use several sheets if necessary)		Filing Date: April 9, 1999	Group: 1653	
	* Rini, J.M., et al., "Crystal Structure Of A Hu Neutralizing Antibody, 50.1, In Complex With Acad. Sci. USA 90:6325-9 (1993).	man Immunodeficiency n Its V3 Loop Peptide Ar	Virus Type 1 tigen", <i>Proc. Natl.</i>	
	* Ritu, et al., "Construction of Synthetic Immu and RESA Proteins of Plasmodium Falciparum	1" Vaccine <b>10</b> (11): 761-	7 <b>6</b> 5 (1992).	
	* Scharpe, S., et al., "Purified And Cell-Bound Binding Profile, And Expression On T Cells In Acad. Geneeskd. Belg., 56:537-559. (1994)	Relation To Other Surfa	ace Markers", Verh. K.	
	Schmitz T., et al., "Potentiation Of The Immur. Invest., 97:1545-1549, (1996).		·	
	* Schon, E., et al., "Dipeptidyl Peptidase IV in Human T Lymphoctyes. An Approach To Role Of A Membrane Peptidase In The Immune System", <i>Biomedica Biochimica Acta</i> , 45:1523-1528 (1986).			
<b>√</b>	* Schon, E., et al., "Dipeptidyl Peptidase IV In The Immune System", Biol. Chem. Hoppe-Seyler, 372:305-311, (1991).			
	* Schön, E., et al., "Dipeptidyl Peptidase IV In Enzyme Inhibitors On The Activity Of Dipepti Lymphocytes", Biological Chemistry Hoppe Se	dyl Peptidase IV And Pro	oliferation Of Human	
	* Schon, E., et al., "The Dipeptidyl Peptidase F Proliferation Lymphocytes", Biomedica Biochii	V, A Membrane Enzyme	Involved In The	
	* Schön, E., et al., "The Role Of Dipeptidyl Peptidase IV In Human T Lymphocyte Activation. Inhibitors And Antibodies Against Dipeptidyl Peptidase IV Suppress Lymphocyte Proliferation And Immunoglobulin Synthesis In Vitro", Eur. J. Immunol. 17:1821-1826 (1987).			
	* Seed, B., "Making Agonists Of Antagonists",	Chemistry & Biology, 1:	125-129 (1994).	
-	* Shimojo, et al., "Identification of the Disease- Epitope-Targeted T Cell Inactivation in Egg Al. 105 (2):155-161 (1994).	Related T Cell Epitope of A lergy" Int'l. Archives of A	of Ovalbumin and Ellergy & Immunol.	
	* Snow, R.J., et al., "Studies On Proline Boroni Peptidase IV: Identification Of A Cyclic Specie Soc., 116:10860-10869, (1994).	c Acid Dipeptide Inhibito es Containing A B-N Box	ors Of Dipeptidyl ad", J. Am. Chem.	
	* Songyang, Z., et al., "SH2 Domains Recogniz 72:767-778, (1993)	e Specific Phosphopeptic	le Sequences", Cell,	
	* Subramanyam, M., et al., "CD26, AT-Cell Ac Specific Immune-Suppression By Inactivation ( Dipeptidyl Peptidase IV (CD26) in Metabolism 162, (1995)	OF CD26: A Clue To The and Immune Response, E	e Aids Paraxox?", in d. B. Fleischer: 155-	
V	* Subramanyam, M., et al., "Mechanism Of Hiv T Cell Responsiveness", J. Immunol., 150:2544	-2553, (1 <u>9</u> 93)		
	Subramanyam, W.G., et al., "Mechanism of HT\ Specific T Cell Responsiveness", J. Immunol. 15	-1 Tat Induced Inhibition	n Of Antigen-	

Form PTO-1449 U.S. Department of Commerce Atty. Docket: In re Application No. (REV. 8-83) Patent and Trademark Office 2002941-0053 09/289.321 INFORMATION DISCLOSURE STATEMENT Applicant: Bachovchin (Use several sheets if necessary) Filing Date: Group: April 9, 1999 1653 \* Sudmeier, J.L., et al., "Solution Structures Of Active And Inactive Forms Of The DP IV (CD26) Inhibitor Pro-Boropro Determined By Nmr Spectroscopy", Biochemistry, 33:12427-12438, (1994). \* Tam, J.P., "Synthetic Peptide Vaccine Design: Synthesis And ProperitiesOf A High-Density Multiple Antigenic Peptide System", Proc. Natl. Acad. Sci. USA, 85:5409-5413, \* Tanaka, T., et al. "Cloning And Functional Expression Of The T Cell Activation Antigen CD26", J. Immunol., 149:481-486. (1992) \* Tanaka, T., et al., "Cloning And Functional Expression Of The T Cell Activation Antigen CD26", J. Immunol. 149: 481-486 (1992); published erratum appears in J. Immunol. 50(5):2090 (1993). \* Tanaka, T., et al., "The Costimulatory Activity Of The CD26 Antigen Requires Dipeptidyl Peptidase IV Enzaymatic Activity", Proc. Natl. Acad. Sci. USA, 90:4586-4590. (1993) \* Thompson, R., "Use Of Peptide Aldehydes To Generate Transition-State Analogs Of Elastase", Biochemistry, 12:1:47-51 (1973). Thompson, R. "Peptide Aldehydes: Potent Inhibitors of Serine and Cysteine Proteases", 19: 220-225, 1973 \* Uibo, et al., "Characterization of Adrenal Autoantigens Recognized by Sera From Patients with Autoimmune Polyglandular Syndrome (APS) Type I. (J. Autoimmunity 7 (3): 399-411 \* Van Noort, et al., "The Small Heat-Shock Protein Alpha B-Crystallin as Candidate Autoantigen in Multiple Sclerosis" Nature 375 (6534):798-801 \* Watson, J.D., "Continuous Proliferation Of Murine Antigen Specific Helper T Lymphocytes in Culture", J. Experimental Medicine 150:1510 (1979). \* Welch, J.T., and Lin J., "Fluoroolefin Containing Dipetide Isoteres As Inhibitors Of Dipeptidyl Peptidase IV (CD26), Tetrahedron, 52:291-304, (1995). Wijdenesnet al "Monoclonal Antibodies (mAb) Against gp130 Imitating Cytokines Which Use the gp130 For Signal Transduction", Abstract. \* Wyss-Coray, T., et al., "Use Of Antibody/Peptides Constructs Of Direct Antigenic Peptides To T Cells: Evidence For T Cells Processing And Presentation", Cellular Immunol., 139 (1):268-73 (1992). \* Yoshimoto, T., et al., "Comparison Of Inhibitory Effects Of Prolinal-Containing peptide Derivates On Prolyl...", (1985) J. Biochem., 98:975-979, (1985) \* Zhu, X., et al., "T Cell Epitope Mapping of Ragweed Pollen Allergen Ambrosia Artemisiifolia (Amb a 5) and Ambrosia Trifida (Amb t 5) and the Role of Free Sulfhydry! Groups in T Cell Recognition" J. Immunol. 155 (10):5064-5073 (1995). \* Zimmerman, D.H., et al. "A New Approach To T-Cell Activation: Natural And Synthetic Conjugates Capable Of Activating T Cells", Vaccine Res., 5:91-102, (1996). Zimmerman, D.H., et al., "Immunication With Peptide Heteroconjugates Primes A T Helper Cell..." Vaccine Res. 5:103-118, (1996).

NO. 858 P. 13

Form PTO-1449 (REV. 8-83)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket: 2002941-0053	In re Application No. 09/289,321	
INFORMATION DISCLOSURE STATEMENT				
DISCLOSURE STATEMENT		Applicant: Bachovchin		
(Use several sheets if necessary)		Filing Date:	Group:	
$\triangle$	$\mathcal{A}$	April 9, 1999	1653	
EXAMINER LAW LINES DATE CONSIDERED 6/10/1			ERED 6/10/04	
EVAMINED. 7-141-1 :c				

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

3184391\_1.DOC